The story of Viagra presents a nuanced case for observers in the drug sector. While initially a blockbuster success, producing huge profits, the exclusivity lapse and the subsequent flood of generic versions have drastically affected earnings. This raises questions about the ongoing profitability of analogous medication developments and suggests th